Beta Bionics reported a gross margin of 59.04% and a net margin of -73.10% for the quarter ended Jun 2026. These financial ratios cover 10 quarters of results from Mar 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross Margin | 55.68% | 53.73% | 53.36% | 57.19% | 50.86% | 53.80% | 55.48% | 58.98% | 59.50% | 59.04% |
| EBT Margin | -64.29% | -71.72% | -60.77% | -59.13% | -91.88% | -72.58% | -52.14% | -41.92% | -79.26% | -73.10% |
| EBIT Margin | -73.09% | -78.32% | -65.71% | -63.78% | -105.69% | -85.52% | -62.54% | -50.20% | -87.86% | -79.90% |
| EBITDA Margin | -73.09% | -78.32% | -65.71% | -63.78% | -105.69% | -85.52% | -62.54% | -50.20% | -87.86% | -79.90% |
| Operating Margin | -73.09% | -78.32% | -65.71% | -63.78% | -105.69% | -85.52% | -62.54% | -50.20% | -87.86% | -79.90% |
| Net Margin | -64.29% | -71.72% | -60.77% | -59.13% | -91.88% | -72.58% | -52.14% | -41.92% | -79.26% | -73.10% |
| FCF Margin | -97.04% | -84.99% | -68.79% | -72.60% | -115.13% | -66.15% | -36.73% | -32.78% | -91.25% | -48.92% |
| Efficiency | ||||||||||
| Inventory AverageInventory Avg. | 14.53M | 16.53M | 18.85M | 21.05M | 22.72M | 23.82M | ||||
| Assets AverageAssets Avg. | 243.83M | 334.00M | 330.01M | 329.39M | 316.58M | 298.40M | ||||
| Asset Utilization RatioAsset Util. | 0.29 | 0.23 | 0.27 | 0.30 | 0.35 | 0.40 | ||||
| Valuation | ||||||||||
| Price to EarningsP/E | -23.20 | -37.52 | -61.51 | -100.38 | -20.39 | -30.12 | ||||
| Price to SalesP/S | 21.31 | 27.23 | 32.07 | 42.08 | 16.16 | 22.02 | ||||
| Price to BookP/B | 1.20 | 2.10 | 2.97 | 4.70 | 1.65 | 2.75 | ||||
| Enterprise Value | 144.48M | 383.13M | 645.43M | 1,132.55M | 246.99M | 524.37M | ||||
| EV to EBIT | -7.75 | -19.28 | -37.87 | -70.24 | -10.18 | -20.50 | ||||
| EV to EBITDA | -7.75 | -19.28 | -37.87 | -70.24 | -10.18 | -20.50 | ||||
| Market Capitalization | 375.95M | 632.85M | 874.11M | 1,351.68M | 446.51M | 704.86M | ||||
| Price to FCFP/FCF | -18.51 | -41.17 | -87.32 | -128.36 | -17.71 | -45.01 | ||||
| EV to FCF | -7.11 | -24.92 | -64.47 | -107.55 | -9.80 | -33.48 | ||||
| EV to CFO | -7.23 | -28.18 | -73.94 | -131.28 | -10.36 | -35.86 | ||||
| Return Ratios | ||||||||||
| Return on Sales [ROS]ROS | -73.09% | -78.32% | -65.71% | -63.78% | -105.69% | -85.52% | -62.54% | -50.20% | -87.86% | -79.90% |
| Return on Capital Employed [ROCE]ROCE | -23.95% | -19.88% | -22.52% | -24.02% | -26.35% | -30.48% | ||||
| Return on Assets [ROA]ROA | -20.19% | -16.56% | -17.99% | -18.44% | -20.99% | -24.45% |